Evidence map›Paper›PMID 37682251›Full record

ArticleJournal of the National Cancer Institute2023

EZH2 inhibition: it's all about the context.

Ezra Y Rosen, Neerav N Shukla, Julia L Glade Bender

Abstract readComment
In one paragraph

Article in Journal of the National Cancer Institute, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Chromatin remodellers as therapeutic targets.Nature reviews. Drug discovery · 2024
    Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Ezra Y RosenDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-5289-1541
Neerav N ShuklaDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Julia L Glade BenderDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
PEP-CTN EHR to RAVE supplementUM1CA228823 · NCI · PUBLIC HEALTH INSTITUTE · PI Elizabeth Fox · 2018 to 2026
$39.6M
Targeting Oncogenic Pathways in Genetically Complex SarcomasP50CA217694 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI William D. Tap · 2018 to 2026
$21.5M
NCI NIH HHS APEC1621HNCI NIH HHS P50 CA217694NCI NIH HHS U10 CA180886NCI NIH HHS UM1 CA228823NIH HHS NCI P30 CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BenzamidesNeoplasmsBiphenyl CompoundsChildDNA HelicasesEnhancer of Zeste Homolog 2 ProteinHumansMorpholinesNuclear ProteinsPyridonesSMARCB1 ProteinTranscription FactorsBenzamidesBiphenyl CompoundsDNA HelicasesEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanMorpholinesNuclear ProteinsPyridonesSMARCA4 protein, humanSMARCB1 ProteinSMARCB1 protein, humantazemetostatTranscription Factors

Identifiers

PMID37682251
PMCPMC10637027

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.